Hypertrophic cardiomyopathy

Lancet

Volumn 350, Issue 9071, 1997, Pages 127-133

  Maron, Barry J ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; GENE MUTATION; GENETIC DISORDER; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MORPHOLOGY; NOMENCLATURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SARCOMERE; SUDDEN DEATH; SYMPTOM;

EID: 0030761751     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)01282-8     Document Type: Review

References (45)

1. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987; 316: 780-89.
2. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy. Prog Cardiovasc Dis 1985; 28: 1-83.
3. Watkins H, Rosenzweig A, Hwang D-S, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326: 1108-14.
4. Schwartz K, Carrier L, Guicheney P, Komajda M. Molecular basis of familial cardiomyopathies. Circulation 1995; 91: 532-40.
5. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995; 92: 1336-47.
6. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995; 26: 1699-708.
7. Spirito P, Seidman CE, McKenna WJ, Maron BJ. Management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-85.
8. Maron BJ, Gardin JM, Flack JM, Gidding SS, Bild D. Assessment of the prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995; 92: 785-89.
9. Rosenzweig A, Watkins H, Hwang D-S, et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med 1991; 325: 1753-60.
10. Maron BJ, Spirito P, Wesley YE, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986; 315: 610-14.
11. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992;85: 1651-60.
12. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction. Circulation 1991; 84: 1188-87.
13. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 8: 545-57.
14. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987; 75: 1130-39.
15. Lechin M, Quiñones MA, Omran A, et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995; 92: 1808-12.
16. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995; 91: 1596-601.
17. Spirito P, Maron BJ. Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987; 9: 1013-17.
18. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and age in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1989; 13: 820-23.
19. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in patients with hypertrophic cardiomyopathy. Am J Cardiol 1987; 60: 123-29.
20. Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle cell disorganisation in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation 1979; 59: 689-706.
21. Tanaka M, Fujiwara H, Onodera T, Wu D-J, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55: 575-81.
22. Nihoyannopoulos P, Karatasakis G, Frenneaux M, McKenna WJ, Oakley CM. Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol 1992; 19: 536-40
23. Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J. Non-invasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987; 10: 733-42.
24. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990; 15: 1279-85.
25. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26: 1529-36.
26. Geisterfer-Lowrance AAT, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996; 272: 731-34.
27. Fox PR, Liu S-K, Maron BJ. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy: an animal model of human disease. Circulation 1995; 92: 2645-51.
28. Shah PM, Adelman AG, Wigle ED, et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res 1973; 34 and 35 (suppl 2): II-179-95.
29. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47: 532-38.
30. Spirito P, Chiarella F, Carratino L, Zoni-Berisso M, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989; 320: 749-55.
31. Kofflard MJ, Waldstein DJ, Vos J, ten Gate FJ. Prognosis in hypertrophic cardiomyopathy: a retrospective study. Am J Cardiol 1993; 72: 939-43.
32. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993; 72: 970-72.
33. Maron BJ, Poliac LC, Casey SA, Lange SK, Aeppli D. Clinical significance and consequences of hypertrophic cardiomyopathy assessed in an unselected patient population: evidence for the relatively benign nature of the true disease state in adulthood. Circulation 1996; 94: I-84 (abstr).
34. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995; 92: 1680-92.
35. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation 1989; 80: 1489-92.
36. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Clinical demographic and pathologic profile of sudden death in 158 young competitive athletes. JAMA 1996; 276: 199-204.
37. Maron BJ, Isner JM, McKenna WJ. Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases, and mitral valve prolaspe. Task Force 3. In: 26th Bethesda Conference. Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities (Maron BJ, Mitchell JH). J Am Coll Cardiol 1994; 24: 880-85.
38. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412-16.
39. Frenneaux MP, Counihan PJ, Caforio ALP, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990; 82: 1995-2002.
40. Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990; 16: 821-26.
41. Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J, Trusler GA. Results of surgery for idiopathic hypertrophic obstructive cardiomyopathy. Circulation 1987; 76 (suppl V): v-104-08.
42. McCully RB, Nishimura RA, Tajik AJ, Schaff HZ, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996; 94: 467-71.
43. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992; 339: 1318-23.
44. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994; 90: 2731-42.
45. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for patients with hypertrophic obstructive cardiomyopathy: a prospective randomized, double-blind cross-over study. J Am Coll Cardiol 1997; 29: 435-41.